Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein–Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD)
RUX was associated with an increased risk of EBV reactivation in patients after allo-HSCT but not with PTLD. Regular monitoring of the EBV viral load to enable timely intervention remains essential in these patients.
Authors
- H. J. Yang (ORCID: https://orcid.org/0009-0004-8274-9863)
- Liping Dou (ORCID: https://orcid.org/0000-0001-7352-9560)
- Daihong Liu
- Yujun Wei
- Fei Li
- Kun Qian
- Lili Wang
- Nan Wang
- Shuangyi Xing
- Zhenyang Gu
Institutions
- Nankai University (CN)
- Chinese PLA General Hospital (CN)
- Central Hospital of Wuhan (CN)
- Wuhan General Hospital of Guangzhou (CN)
Publication Details
- Journal
- Cancer Pathogenesis and Therapy
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1016/j.cpt.2025.12.001
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00